Promoting brain repair in MS with a natural compound that nudges neural stem cells
Official title: Harnessing endogenous neural progenitor cells with a natural product-derived Notchsignaling inhibitor for CNS repair in multiple sclerosis
Funded at University of Illinois at Urbana-Champaign · NIH-11443028 · Data updated 2026-11-12
A researcher is testing a natural-product–based compound that may help people with multiple sclerosis repair nerve damage by guiding brain stem cells to become neurons and myelin-producing cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Urbana-Champaign NIH-funded |
| Lab location | 1 site (Champaign, United States) |
| Project start | August 21, 2026 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $407,211 |
| NIH project number | 1R01NS153446-01 |
| Project ID | NIH-11443028 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with multiple sclerosis or related CNS demyelinating conditions may be eligible in future translational steps and trials.
✕Less likely to help
Immediate benefit is unlikely; early-stage preclinical work may not translate to all patients.
What this research studies
This project aims to use a natural product–derived Notch signaling inhibitor to stimulate endogenous neural progenitor cells in the central nervous system, encouraging them to differentiate into neurons and oligodendrocytes so repair can occur in MS. The work will combine in vitro studies and animal models to uncover how (+)-3d-spiro-oxindole drives this differentiation and reduces inflammation. If successful, it could lead to a new therapeutic approach that supports brain and spinal cord repair in people with MS.
Why it matters
Potential benefit: If successful, patients with MS could benefit from improved neural repair and reduced neuroinflammation.
How similar studies have gone: Preclinical models have shown neurogenic and remyelinating effects with related compounds, supporting potential efficacy but requiring confirmation in humans.
Where this research is happening
-
University of Illinois at Urbana-Champaign
Champaign, United States Active
Researchers
- Principal investigator: Inoue, Makoto — University of Illinois at Urbana-Champaign
- Study coordinator: Inoue, Makoto
Related research
Other NIH-funded projects on the same topics.
-
Susceptibility-based MRI biomarkers for multiple sclerosis
A short-term study aims to test MRI biomarkers that could help diagnose and predict MS in patients, using advanced imaging techniques.
-
Mediterranean-style eating and aging in people with multiple sclerosis
This project looks at whether following a Mediterranean-style diet is linked to slower biological aging and less brain shrinkage in people living with multiple sclerosis.
-
Imaging brain energy use in multiple sclerosis with a new imaging method
A new MRI-based method will non-invasively measure how the brain uses glucose and ketones in people with multiple sclerosis.
-
Astrocyte exosomes as aging biomarkers and drivers of MS progression
Researchers are testing a blood-based biomarker from astrocyte-like exosomes to understand why multiple sclerosis gets worse with age and to identify potential targets for treatment.
-
Targeted B cell tolerance therapy for multiple sclerosis using Ace-DEX microparticles
A new therapy using tiny biopolymer particles given through the vein aims to retrain B cells to tolerate the immune system in people with multiple sclerosis.
-
Low-Load BFR Training to Help People with Advanced MS Improve Strength
A randomized trial tests whether low-load resistance training with blood flow restriction can improve muscle strength for people with advanced multiple sclerosis.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.